BIOA$5.88+1.38%
BioAge Labs, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$269.87M
Float & O/S:
Inst Own:
DilutionScan read 35 of BioAge Labs, Inc.'s SEC filings and found 3 warrant series, 2 convertibles, 1 ATM program, 3 shelf registrations and 4 completed offerings on file for BIOA. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
BIOA
Unprofitable biotech with comfortable cash runway
Snapshot
BioAge is a clinical-stage biotech burning cash to develop drugs for metabolic diseases. It reported $9M in revenue for FY 2025 but lost $80.6M. The company spends heavily on R&D, burning roughly $82M in free cash flow annually.
What's Happening Right Now
- : The stock fell following disappointing Phase 3 cardiovascular trial results from competitor Novo Nordisk, which sparked concerns about the broader NLRP3-targeting therapy class.
- : The company dosed the first participant in the Phase 2 QUELL-CV trial for BGE-102, evaluating the drug in patients with elevated cardiovascular risk, with topline data expected in the second half of 2026.
- : The company reported Q1 2026 financial results, highlighted positive Phase 1 data for BGE-102, and announced the completion of a $132.3 million follow-on public offering to bolster its balance sheet.
